Pharmacodynamics Part 1

⭐ 1. Q: What is pharmacodynamics (PD), and how is it different from pharmacokinetics (PK)?

Pharmacodynamics (PD) describes what a drug does to the body, whereas pharmacokinetics (PK) describes what the body does to the drug and determines drug concentration over time.

PK includes:

• absorption

• distribution

• metabolism

• excretion

2. Q: Why is pharmacodynamics clinically important when treating disease?

Pharmacodynamics is clinically important because drugs can increase or decrease altered physiological signaling to restore or improve function.

3. Q: What major molecular targets can drugs act on?

Drugs can act on receptors, ion channels, enzymes, and transporters, which are usually proteins that control different cellular processes.

Receptors

• bind endogenous ligands and drugs

• convert binding into a biological response

Ion channels

• control movement of ions across membranes

• regulate things such as excitability and muscle contraction

Enzymes

• catalyze biochemical reactions

• drugs can inhibit or modify their activity

Transporters

• move molecules across cell membranes

• drugs can inhibit them or compete for transport

⭐ 4. Q: What is a receptor, and what determines where and with which ligands it interacts?

A receptor is a macromolecule that recognizes a ligand and converts that interaction into a biological response, while receptor structure and tissue expression determine which ligands can bind and where effects occur.

🔎 What this means:

Normal endogenous, or naturally produced, ligands include:

• hormones

• neurotransmitters

• growth factors

Drugs can bind to these same receptors and change their activity.

Receptors are selective because their structure determines which ligands can fit and interact with them.

Receptor expression also differs among tissues. Therefore, a drug may produce strong effects in one tissue but little effect in another because the receptor may be present in different amounts.

Examples:

• epinephrine → β-adrenergic receptor

• acetylcholine → muscarinic receptor

• endogenous opioids → μ-opioid receptor

⭐ Q: How can agonists and antagonists be used to correct abnormal physiological activity?

Agonists can increase receptor signaling when physiological activity is too low,

while antagonists can decrease receptor signaling when physiological activity is too high.

🔎 What this means:

An agonist activates a receptor and can increase signaling or function.

The lecture gives examples such as increasing:

• heart rate when it is excessively slow

• airway diameter during bronchoconstriction

• contractility when appropriate

An antagonist binds a receptor without activating it and can reduce or prevent receptor activation.

The lecture gives examples such as decreasing:

• excessive sympathetic stimulation

• inappropriate receptor activation

• excessive physiological responses

💡 Think:
Too little activity → agonist can turn it up.
Too much activity → antagonist can turn it down.

5. Q: What determines whether a ligand can bind to a receptor?

Ligand-receptor binding depends on molecular complementarity, including the ligand's shape, size, chemical properties, and intermolecular forces with the receptor.

💡 Think: Binding requires both a good physical fit and compatible chemical interactions.

🔎 What this means:

A ligand must physically and chemically interact appropriately with the receptor's binding site.

The lecture identifies:

Shape and size

• the ligand must fit the binding site

Chemical properties

• charge

• polarity

• hydrophobic regions

Intermolecular forces

• van der Waals forces

• hydrogen bonds

• ionic interactions

• rarely, covalent bonds

⭐ 6. Q: How does receptor binding lead to a biological response?

Receptor binding leads to a biological response because ligand binding can activate the receptor and initiate signal transduction, which changes cellular function and ultimately produces tissue or organ effects.

• The ligand binds the receptor.

• Binding activates the receptor.

• Receptor activation starts signal transduction.

• Signaling changes cellular function.

• Cellular changes produce a tissue or organ response.

⭐ 7. Q: What is drug affinity, and how does the dissociation constant (KD) describe it?

Affinity describes how strongly a ligand binds to its receptor, and KD is the ligand concentration at which 50% of receptors are occupied.

🔎 What this means:

A drug with high affinity binds strongly, so relatively little drug is needed to occupy receptors aka lower KD bc it needs less ligands

A drug with low affinity binds less strongly, so a higher concentration is needed to achieve the same receptor occupancy aka higher KD bc it needs more ligands

The important relationship is:

• lower KD → higher affinity

• higher KD → lower affinity

8. Q: iClicker — Drug A has a KD of 2 nM and Drug B has a KD of 50 nM at the same receptor. Which statement is correct?

A. Drug A must produce a greater maximal response.
B. Drug B has greater affinity for the receptor.
C. Drug A has greater affinity for the receptor.
D. Drug B must be a receptor antagonist.

Correct answer is C: Drug A has greater affinity for the receptor because its lower KD means less drug is required to occupy the receptor.

⭐ 9. Q: How do full agonists, partial agonists, and antagonists differ after binding to a receptor?

A full agonist activates the receptor and can produce a maximal response, a partial agonist activates it but produces a smaller maximal response, and an antagonist binds without activating it and can prevent or reduce agonist activation.

🔎 What this means:

All three can bind the same receptor.

What differs is what happens after binding.

Full agonist

• binds

• activates the receptor

• can produce a maximal response

Partial agonist

• binds

• activates the receptor

• produces a submaximal response, even at high concentrations

Antagonist

• binds

• does not activate the receptor

• can prevent or reduce receptor activation by an agonist

So simply knowing that a drug binds a receptor does not tell you what functional response it will produce. 2026 VM500 Pharmacodynamics pt …

💡 Think:
Full agonist = full activation
Partial agonist = partial activation
Antagonist = binding without activation

10. Q: How does increasing the concentration of an agonist affect its biological response?

Increasing the concentration of an agonist generally increases receptor activation and biological response until the drug reaches its maximum achievable effect, or Emax.

At a low concentration:

• relatively few receptors are activated

• response is small

As concentration increases:

• more receptor activation occurs

• the response becomes larger

⭐ 11. Q: Why is a partial agonist not simply a less potent full agonist?

A partial agonist is not simply less potent because its defining feature is a lower maximum achievable response, even though it may bind with high affinity and act at relatively low concentrations.

This distinction is extremely important.

Potency asks:

How much drug is needed to produce an effect?

A partial agonist may act at a low concentration, meaning it could still be quite potent.

But efficacy asks:

What is the greatest effect the drug can ultimately produce?

A partial agonist cannot reach the same Emax as a full agonist, even when the partial agonist concentration becomes very high.

So:

Partial agonist ≠ weakly potent agonist

It has a lower maximum response, not necessarily a requirement for more drug.

⭐ 12. Q: What is the difference between graded and quantal drug responses?

A graded response measures how much effect occurs in an individual or experimental system,

whereas a quantal response measures whether a defined effect occurs or not in each individual, then evaluated across a population.

Graded Response examples:

Asks:

“How much effect?”

• amount of blood-pressure decrease

• amount of heart-rate increase

• percentage of muscle contraction

It may be measured in an:

• individual

• tissue

• experimental system

Quantal Response:

Asks:

“Did the effect happen or not?”

For each individual, the outcome is essentially yes or no.

Examples:

• Was the animal sedated?

• Was the seizure prevented?

• Did toxicity occur?

The results are then evaluated across a population.

⭐ 13. Q: What is EC50, and how does it describe drug potency on a graded concentration-response curve?

EC50 is the drug concentration that produces 50% of that drug's maximal effect, and a lower EC50 indicates greater potency.

🔎 What this means:

Potency describes how much drug is required to produce a defined effect.

If Drug A reaches 50% of its maximum effect at a lower concentration than Drug B, Drug A is more potent.

Therefore:

• lower EC50 → greater potency

• higher EC50 → lower potency

On a concentration-response graph, the more potent drug is positioned farther to the left because it achieves its effects at lower concentrations.

The lecture emphasizes that potency is comparative: you compare how much of different drugs is needed for an effect.

💡 Think: Potent = need less drug.

⭐ 14. Q: What is Emax, and how does it describe drug efficacy?

Emax is the maximum response a drug can produce, and a higher Emax indicates greater efficacy.

🔎 What this means:

Efficacy asks:

What is the greatest effect this drug is capable of producing?

On a concentration-response graph, efficacy is represented by the height of the curve.

A drug with a higher plateau has a higher Emax and therefore greater efficacy.

Importantly:

Potency and efficacy are not the same thing.

A drug can require very little drug to produce an effect, making it more potent, but still have a lower maximum effect, making it less efficacious

💡 Think:
Potency = how much drug?
Efficacy = how much effect?

⭐ 15. Q: How do affinity, potency, and efficacy describe different properties of drug action?

Affinity describes how strongly a drug binds,

potency describes how much drug is needed for an effect,

and efficacy describes the maximum effect the drug can produce.

🔎 What this means:

These three concepts answer three different questions.

Affinity

Measured using KD.

A lower KD means higher affinity.

Potency

For a graded response, this is commonly compared using EC50.

A lower EC50 means greater potency.

Efficacy

Described by Emax.

A higher Emax means greater efficacy.

A drug can therefore have high affinity but low efficacy, or be more potent but less efficacious than another drug.

💡 Think:
Affinity = binding
Potency = amount needed
Efficacy = maximum effect

⭐ 16. Q: How do you identify greater potency, greater efficacy, and a partial agonist on a graded concentration-response graph?

On a graded concentration-response graph:

1. Greater potency appears as a leftward curve

2. Greater efficacy appears as a higher maximum response

3. A partial agonist has a lower maximum response than a full agonist.

Potency

• Drug A is more potent than Drug B.

• A and C have similar potency if their EC50 values are the same.

Efficacy

Look vertically at the maximum height.

• Drugs A and B reach the greatest maximum response.

• Drug C plateaus at a lower response.

Therefore Drug C has lower efficacy and could represent a partial agonist.

💡 Think:
Left/right = potency
Up/down = efficacy

17. Q: Why are graded concentration-response curves commonly plotted using a logarithmic concentration axis?

A log concentration axis makes a wide range of drug concentrations easier to display and spreads out the part of the curve where the response changes most.

⭐ 18. Q: What does ED50 mean in a quantal dose-response relationship?

ED50 is the dose that produces a defined effect in 50% of the population.

🔎 What this means:

Remember that a quantal response asks whether an effect occurred in each individual.

For example, the lecture uses sedation in 100 dogs.

At the ED50:

50 out of 100 dogs would show the defined effect.

So ED50 does not mean that every dog experiences “half sedation.”

Instead, each individual either meets the definition of sedation or does not, and ED50 describes the population percentage responding.

The lecture's slide 23 shows this graphically using sedation as the defined outcome.

💡 Think: ED50 = effect occurs in half the population.

The purpose of ED₅₀ is to give you a standard way to describe how much drug is needed to produce a defined effect in a population.

So if the defined effect is sedation in dogs, and the ED₅₀ is 0.1 mg/kg, that means:

At 0.1 mg/kg, about 50% of the dogs are sedated.

It does not mean each dog is “50% sedated.”

19. Q: What is the difference between a frequency-distribution graph and a cumulative quantal dose-response graph?

A frequency distribution shows how individual response thresholds are distributed across doses,

whereas a cumulative quantal curve shows the percentage of the population that has responded by each dose.

Frequency distribution

• shows the number of animals that first respond at each dose

• often looks like a bell-shaped distribution

• the peak represents the dose range at which the most animals first respond

Cumulative quantal curve

• continually adds everyone who has already responded

• shows the percentage responding at or below each dose

• allows ED50 to be read as the dose where 50% have responded

⭐ 20. Q: What are ED50, TD50, and LD50 in quantal dose-response analysis?

ED50 is the dose producing the desired effect in 50% of the population,

TD50 produces a defined toxic effect in 50%,

and LD50 causes death in 50%.

🔎 What this means:

Quantal analysis can be applied to different yes/no outcomes.

ED50: Effective Dose 50

Desired effect occurs in 50% of the population.

TD50: Toxic Dose 50

Defined toxic effect occurs in 50% of the population.

LD50: Lethal Dose 50

Death occurs in 50% of the population.

The “50” always refers to 50% of the population, but the outcome being measured differs

⭐ 21. Q: How are KD, EC50, and ED50 different?

KD describes receptor binding affinity,

EC50 describes the concentration producing 50% of a drug's maximal graded response,

and ED50 describes the dose producing a defined quantal effect in 50% of a population.

🔎 What this means:

These all contain “50,” but they describe different things.

KD

• concerns receptor occupancy

• ligand concentration at which 50% of receptors are occupied

• lower KD means greater affinity

EC50

• concerns a graded response

• concentration producing 50% of that drug's maximal effect

• lower EC50 means greater potency

ED50

• concerns a quantal population response

• dose at which 50% of individuals show the defined effect

So:

KD is about binding.
EC50 is about how much response one system produces.
ED50 is about how many individuals respond.

💡 Think:
KD → receptors
EC50 → graded effect
ED50 → population

22. Q: How do morphine, buprenorphine, and naloxone illustrate different ligand types at the μ-opioid receptor?

Morphine acts as a full agonist, buprenorphine acts as a partial agonist, and naloxone acts as an antagonist at the μ-opioid receptor.

🔎 What this means:

All three drugs act at the same receptor, but they produce different functional effects.

Morphine

• binds the μ-opioid receptor

• activates it

• produces a substantial maximal response

• therefore acts as an agonist

Buprenorphine

• binds the receptor with high affinity

• activates it

• produces a lower maximal response than the full agonist

• therefore acts as a partial agonist

Naloxone

• binds the receptor with high affinity

• produces no receptor activation

• blocks activation by opioid agonists

• therefore acts as an antagonist

This example reinforces that high affinity does not automatically mean high efficacy.

⭐ 23. Q: iClicker — Three drugs have high affinity for the same receptor: Drug A produces a maximal response, Drug B produces a lower maximal response, and Drug C produces no response alone. Which interpretation is most likely correct?

A. Drug A is a full agonist, Drug B is a partial agonist, and Drug C is an antagonist.
B. Drug A is the most potent because it has the greatest efficacy.
C. Drug B has lower affinity because it produces a smaller response.
D. Drug C cannot bind the receptor because it produces no response.
E. All three drugs have the same efficacy because they bind the same receptor.

Choice A is correct because Drug A behaves as a full agonist, Drug B as a partial agonist, and Drug C as an antagonist.